ID   NCI-H548
AC   CVCL_1570
SY   NCI H548; H548; H-548; NCIH548
DR   CLO; CLO_0008097
DR   ATCC; CCL-249
DR   BioSample; SAMN03471379
DR   GEO; GSM1374755
DR   KCLB; 10249
DR   PRIDE; PXD005354
DR   PRIDE; PXD005355
DR   Wikidata; Q54908077
RX   PubMed=3479249;
RX   PubMed=8806092;
RX   PubMed=8806095;
RX   PubMed=18258742;
RX   PubMed=20606684;
RX   PubMed=23272949;
RX   PubMed=29101300;
CC   Part of: AstraZeneca Colorectal cell line (AZCL) panel.
CC   Omics: Deep proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: ATCC; CCL-249; true.
CC   Derived from site: In situ; Colon, sigmoid; UBERON=UBERON_0001159.
ST   Source(s): ATCC=CCL-249; KCLB=10249
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 9,11
ST   D16S539: 11,13
ST   D3S1358: 16
ST   D5S818: 12,13
ST   D7S820: 9,11
ST   FGA: 21,22
ST   TH01: 7
ST   TPOX: 10,11
ST   vWA: 15,18 (KCLB=10249)
ST   vWA: 15,18,19 (ATCC=CCL-249)
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 19
//
RX   PubMed=3479249;
RA   Park J.-G., Oie H.K., Sugarbaker P.H., Henslee J.G., Chen T.-R.,
RA   Johnson B.E., Gazdar A.F.;
RT   "Characteristics of cell lines established from human colorectal
RT   carcinoma.";
RL   Cancer Res. 47:6710-6718(1987).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=8806095; DOI=10.1002/jcb.240630508;
RA   Park J.-G., Gazdar A.F.;
RT   "Biology of colorectal and gastric cancer cell lines.";
RL   J. Cell. Biochem. 63 Suppl. 24:131-141(1996).
//
RX   PubMed=18258742; DOI=10.1073/pnas.0712176105;
RA   Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.;
RT   "Cell growth, global phosphotyrosine elevation, and c-Met
RT   phosphorylation through Src family kinases in colorectal cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=23272949; DOI=10.1186/1755-8794-5-66;
RA   Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A.,
RA   Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A.,
RA   Orphanides G., French T., Wessels L.F.A.;
RT   "Subtypes of primary colorectal tumors correlate with response to
RT   targeted treatment in colorectal cell lines.";
RL   BMC Med. Genomics 5:66.1-66.15(2012).
//
RX   PubMed=29101300; DOI=10.15252/msb.20177701;
RA   Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S.,
RA   Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S.,
RA   Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J.,
RA   Weichert W., Knapp S., Feller S.M., Kuster B.;
RT   "Pharmacoproteomic characterisation of human colon and rectal
RT   cancer.";
RL   Mol. Syst. Biol. 13:951-951(2017).
//